Acrux Ltd (ARUXF) 0.5300 $ARUXF Female Sexual

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acrux Ltd (ARUXF) 0.5300 $ARUXF

Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc.
M2 - Mon Jan 18, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/s2x472/female_sexual) has announced the addition of the "Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015" provides an overview of Female Sexual Dysfunction clinical trials scenario. This report provides top line data relating to the clinical trials on Female Sexual Dysfunction. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Companies Mentioned: - Emotional Brain BV - Sprout Pharmaceuticals, Inc. - Pfizer Inc. - Allergan Plc - ANI Pharmaceuticals, Inc. - Vivus, Inc. - Strategic Sciences and Technologies, LLC - Palatin Technologies, Inc. - Acrux Limited - Apricus Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/s2...ale_sexual
AGN: 234.02 (+2.93), ANIP: 57.31 (+1.49), PFE: 35.57 (+0.36), PTN: 0.49 (+0.05), APRI: 0.39 (-0.01)

Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (8) - - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 16.98 (+1.39), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 78.95 (+0.20), ABBV: 62.71 (+0.80), CBRX: 7.36 (+0.45), ATRS: 1.10 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading

Top 5 Most Recently Viewed Articles

3Srobotics Breaks Ground with North American Debut

Updated Category News Views 204

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025

Updated Category News Views 912

Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...

Continue Reading
Vivos Therapeutics to Share Q1 2025 Results and Updates Soon

Updated Category News Views 257

Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...

Continue Reading
Join XBP Global for the Annual Turkey Trot This Thanksgiving

Updated Category News Views 217

XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...

Continue Reading
Market Reaction to CEO Departure and Boot Barn's Strong Quarter

Updated Category News Views 317

Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...

Continue Reading